Mayne Pharma Group Limited

Mayne Pharma reported 1H fiscal '26 revenue of $212.1 million, broadly flat year over year. Gross margin improved to 65.3% from 61.4% in the prior corresponding period. Underlying EBITDA was $28.6 million, down 8%, total direct segment contribution increased 5% to $68.1 million, and adjusted operating cash flow from continuing operations was $16.9 million. Cash and marketable securities closed the half at $67.3 million. By segment, Women's Health revenue was $96.5 million, up 2%, with gross profit of $76.2 million, down 1%, gross margin of 79% and direct contribution of $36.2 million, down 8%; Dermatology revenue was $78.6 million, down 3%, with gross margin of 65% and direct contribution of $29.8 million, up 35%; International revenue was $36.9 million, down 1%, with gross profit of $11.3 million, up 7%, gross margin of 30.5% and direct contribution of $2.1 million, down 42%. Management did not provide formal numeric full-year or next-quarter guidance, but said it expects revenue growth to normalize to at least TRx growth once prior-year credits roll off, expects legal and transaction costs to come down over time, and expects FDA post-approval study costs to step down beginning in fiscal '27.

Aaron Gray framed the company as in a strong position with a differentiated portfolio, improving commercial execution and continued cash discipline. He emphasized continuity through the planned leadership transition and said the business is stable with an experienced management team, while also outlining strategic priorities across Women's Health, Dermatology and International. His tone was confident but measured, stressing disciplined capital allocation and a focus on sustainable growth rather than near-term revenue at any cost.

The financial message centered on quality of earnings and cash generation despite significant one-offs. Gray said underlying EBITDA excludes a $54.5 million noncash earn-out reassessment and $21.3 million of diligence, business development, litigation and restructuring charges, while the half also included $20.7 million of scheme-related transaction and litigation costs, $7.3 million in royalties, $10.3 million tied to TWYNEO and EPSOLAY intangible acquisition costs, and $5.1 million of discontinued operations cash outflows. He highlighted $16.9 million of adjusted operating cash flow from continuing operations, $67.3 million of cash and marketable securities, and said net CapEx was only $1.3 million, reinforcing that the core business remained cash generative. He also said FDA post-approval study costs stepped up by about $2.6 million versus the prior first half and should step down beginning in fiscal '27.

Analysts focused on three issues: whether Women's Health can keep converting script growth into revenue growth, how management will handle ANNOVERA product returns, and what happens as RHOFADE faces generic competition later in fiscal '26. Gray said Women's Health revenue lagged Rx growth partly because ANNOVERA returns and a non-repeating prior-year credit distorted the comparison, but he expects revenue growth to track or exceed TRx growth once normalized. On ANNOVERA, he said the product is structurally challenging because of its multi-month prescription profile and wholesale return rights, and the company is using a more targeted access approach and alternative wholesalers to reduce returns. On RHOFADE, he said the company knew the asset was not long-lived and expects competition at the end of fiscal '26, but will take steps to protect market share.